Cenicriviroc - Tobira Therapeutics
Alternative Names: Cenicriviroc mesylate; CVC; TAK-652; TBR-652Latest Information Update: 26 Jul 2024
At a glance
- Originator National Institute for Health Research; Takeda
- Developer AbbVie; Charite - Universitatsmedizin Berlin; Dong-A ST; Imperial College of Science, Technology and Medicine; National Institute for Health Research; Novartis; Quantum Leap Healthcare Collaborative; Tobira Therapeutics; University of Hawaii
- Class Amides; Anti-inflammatories; Antifibrotics; Antineoplastics; Antiretrovirals; Hepatoprotectants; Imidazoles; Nootropics; Small molecules
- Mechanism of Action CCR2 receptor antagonists; CCR5 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cognition disorders; COVID 2019 infections; HIV-1 infections; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Primary sclerosing cholangitis
- No development reported Cancer; Cholestasis; Diabetic nephropathies; Graft-versus-host disease; Liver disorders
Most Recent Events
- 19 Jun 2024 National Institute of Allergy and Infectious Diseases (NIAID) in collaboration with AbbVie completes a phase II trial for HIV-1-infection in USA (NCT05630885)
- 04 Jan 2024 Discontinued - Phase-III for Non-alcoholic steatohepatitis in Slovenia, Switzerland, Switzerland, Singapore, Taiwan, Portugal, New Zealand, Romania, Russia, Peru, Norway, Mexico, Israel, Hungary, Greece, Georgia, Chile, Canada, Austria, Poland, Germany, Belgium, Latvia, Puerto Rico, USA, Australia, United Kingdom, France, Spain, Hong Kong, Italy, Argentina, Brazil, India (PO) Prior to January 2024 (AbbVie pipeline, January 2024)
- 30 May 2023 National Institute of Allergy and Infectious Diseases (NIAID) in collaboration with AbbVie initiates enrolment in a phase II trial for HIV-1-infection in US (NCT05630885)